Last reviewed · How we verify
Eplerenone (Morning)
Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss.
Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss. Used for Heart failure with reduced ejection fraction, Post-myocardial infarction left ventricular dysfunction, Hypertension.
At a glance
| Generic name | Eplerenone (Morning) |
|---|---|
| Also known as | Inspra |
| Sponsor | Vanderbilt University Medical Center |
| Drug class | Selective aldosterone antagonist |
| Target | Mineralocorticoid receptor (MR) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Eplerenone selectively inhibits aldosterone binding to mineralocorticoid receptors, preventing aldosterone-mediated sodium reabsorption and potassium excretion in the collecting duct. This leads to increased sodium and water excretion, reduced blood volume and blood pressure, and decreased cardiac fibrosis and remodeling. Unlike non-selective aldosterone antagonists, eplerenone has minimal affinity for other steroid receptors, reducing hormonal side effects.
Approved indications
- Heart failure with reduced ejection fraction
- Post-myocardial infarction left ventricular dysfunction
- Hypertension
Common side effects
- Hyperkalemia
- Dizziness
- Fatigue
- Abdominal pain
- Diarrhea
Key clinical trials
- Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects (PHASE1)
- Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone (PHASE2)
- Diurnal Variation of Plasminogen Activator Inhibitor-1 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eplerenone (Morning) CI brief — competitive landscape report
- Eplerenone (Morning) updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI